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Background:There were no documents about the non-lung involvement of COVID-19, even in the absence of 
lung involvement. The present study aimed to report a single-centre experience of liver involvement caused by 
COVID-19 disease in Iran. 
MaterialsandMethods:We recorded information of 120 patients who suffered COVID-19 disease, and they 
were admitted to the intensive care unit at Taleghani hospital in Tehran, Iran, between March and May 2020. 
Along with clinical and diagnostic parameters, the outcome of patients concerning improvement, disease 
progression or death was also assessed. 
Results:In total, 68 patients (56.7%) had abnormal liver dysfunction. The most common changes in liver-
related parameters were elevated international normalized ratio (INR) (mean serum level of 2.5) followed by 
elevated alkaline phosphatase (ALP) (mean serum level of 412 mg/dl). The mean level of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) increased 4 and 9 times more than the 
standard limit. The overall death rate in COVID-19 patients was 38 patients (55.88%, n=68). 
Conclusion:Liver injuries are common findings in patients suffering COVID-19 infection and leading to poorer 
outcomes. Serum bilirubin level of more than 3mg/dl was associated with higher mortality in patients with liver 
damage. 
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Introduction 
In December 2019, a series of pneumonia patients 
were diagnosed with an unknown cause in Wuhan, 
China, and quickly spread around the world1. A new 
type of coronavirus, known as COVID-19, was 
identified by analyzing the genomic sequence 
responsible for pneumonia2. As of February 2020, 
72,436 cases of coronavirus have been identified in 31 
Chinese states, resulting in 1,688 deaths in that 
country3,4. After the first reports from Wuhan, China, 
other cases worldwide have been gradually identified 
and reported in the United States, Italy, Spain, Iran, 
Japan, and other parts of the world5-8. In January 2020, 
the World Health Organization identified COVID-19 
as a global epidemic9. The virus has a high potential 
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for person-to-person transmission, leading to 
numerous reports of its spread worldwide10-16. 
In recent months, extensive efforts have been made 
to describe the epidemiology, clinical manifestations, 
and clinical features of COVID-19. What has 
recently attracted the attention of many researchers 
has been the out-of-lung involvement of the disease, 
even in the absence of lung involvement. In this 
regard, liver injuries have been much highlighted17. 
To date, the extensive studies on COVID-19 could 
reveal elevated serum levels of liver 
aminotransferases and Bilirubin in a majority of 
patients who are suffering COVID-19. Although 
significant liver dysfunction was not reported in 
some studies, some others have suggested the 
increased risk of liver dysfunction and even failure 
following COVID-19 infection18-20. Close inspection 
of the available data supports a higher prevalence of 
abnormal aminotransferase levels in severe COVID-
19 disease, but these studies suggest that clinically 
significant liver injury is uncommon, even when data 
for the most severely ill patients are selected21,22. 
Some studies have hypothesized that hepatic 
congestion might be caused by increasing right atrial 
pressure and impeding venous return following 
mechanical ventilation, but others could show such 
liver injuries without mechanical ventilation23. Also, 
it seems that the applied therapeutic regimens for 
treating and controlling COVID-19 infection may be 
hepatotoxic, and thus it has been known as drug-
induced liver injury24. Some studies hypothesized 
that liver injuries might be due to the direct invasion 
of the virus to liver tissue causing viral hepatitis25, 
but such suggestions have not been exclusively 
assessed. However, what is certain is that liver 
involvement, for whatever reason and pathogenesis, 
is associated with the adverse outcome of the disease 
and can lead to disease progression and even death. 
The present study aimed to report a single-center 
experience of liver involvement during COVID-19 
infection in Iran. 
Methods 
Approval of this study was obtained from The 
Medical Ethical Committee (Approval no: 
IR.SBMU.RIGLD.REC.1400.008) at Shahid 
Beheshti University of Medical Sciences, Tehran, 
Iran. In the present report, the hospital recorded all 
patients who suffered COVID-19 infection and were 
admitted to the intensive care unit (ICU) at Taleghani 
hospital in Tehran between March and May 2020 were 
retrospectively assessed. In addition to collecting the 
baseline characteristics, including demographics, 
clinical manifestations and therapeutic regimens, all 
laboratory parameters recorded in the hospital files 
were assessed potentially in terms of the changes in 
liver function tests. Along with clinical and diagnostic 
parameters, the outcome of patients concerning 
improvement, disease progression, or death was also 
assessed. In this study, the patients with a history of 
hepatitis, hepatic cirrhosis, or related cancers were 
excluded from the final assessment. The results were 
presented as mean±standard deviation (SD) for 
quantitative variables and were summarized by 
absolute frequencies and percentages for categorical 
variables. Categorical variables were compared using 
the chi-square test or Fisher's exact test when more 
than 20% of cells with an expected count of less than 
five were observed. Quantitative variables were also 
compared with the t-test or Mann U test. The 
statistical software SPSS version 16.0 for windows 
(SPSS Inc., Chicago, IL) was used for the statistical 
analysis. P values of 0.05 or less were considered 
statistically significant. 
Results 
A total of 120 patients with a definitive diagnosis of 
COVID-19 were admitted to ICU. Almost 37.5% were 
women, and 62.5% were men. The average age of 
participants was 68.42±6.45 years in the male group 
and 61.31±5.79 years in the female group. Fifty-one 
patients (75%) had a history of smoking, and 65 
(95.5%) showed respiratory symptoms, including 
shortness of breath or cough, and 57 (83.8%)  patients 
had a typical chest CT scan. 
Overall, 108 out of 120 evaluated patients (90.0%) had 
evidence of lung involvement, 68 patients (56.7%) had 
abnormal liver dysfunction, defined as increasing INR, 
ALT, AST, ALP or Bilirubin. Among the Patients 
with hepatic dysfunction, 29 (42.6%) were men, 39 
(57.3%) were female, and 85.2% were over 50 years 
old. Of all 68 patients with liver involvement, 3 
(4.4%) had no simultaneous lung involvement. Sixty-
three patients (92.6%) with abnormal LFT had a 
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history of abdominal pain, compared with 18 patients 
(15.3%) in the group with normal LFT. 
The characteristics of liver parameters on admission in 
the patients with liver involvement are presented in 
Table 1: Liver parameters in population with liver injury following COVID-19. 
Parameter  Mean level Lower limit Higher limit 
Serum ALT 140 60 220 
Serum AST 308 50 465 
Serum ALKp 412 320 2305 
Serum bilirubin  2.8 1.5 14.5 
Serum INR 2.5 1.5 5.0 
 
 
Table 2: Comparison between patients with abnormal and normal liver function test. 
 Abnormal Liver Function Test Normal Liver Function Test 
Male 42.6% 28.8% 
Female 57.3% 71.1% 
Age> 50 year 85.2% 88.4% 
Smoking 75% 65.3% 
respiratory symptoms 95.5% 92.3% 
Typical Chest CT scan 83.8% 98.07% 
Abdominal Pain 92.6% 34.6% 
hospitalization > 15 days 17.6% 15.3% 
Death 30.8% 32.6% 
Septic Shock 26.4% 32.6% 
AKI (↑Cr) 51.4% 40.3% 
Ecmo 0 0 
CRRT 1.4% 0 
Invasive mechanical ventilation 69.11% 84.61% 
Non-invasive mechanical ventilation 30.8% 15.3% 
DM 14.7% 13.4% 
Poor control DM (HbA1c>7) 13.2% 11.5% 
↑ LDH 83% 69% 
Blood group O+ 39% 32% 
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Table 1. In this regard, the most common changes in 
liver-related parameters were elevated INR (mean 
serum level of 2.5) followed by elevated ALP (mean 
serum level of 412 mg/dl). The mean level of direct 
Bilirubin was 2.8 mg/dl, and the mean level of ALT 
was 140 mg/dl (four times more than the standard 
limit), and the mean level of AST was 308 mg/dl 
(nine times more than the standard limit). Elevated 
lactate dehydrogenase (LDH) was also seen in 74 
patients (86.0%), that 57 of them were among 
patients with liver dysfunction. In those patients with 
injured liver, 27(39%) of patients with liver damage 
had blood group O, vs 17 (32%) of patients in the 
opposite group.   
The mean admission day to ICU was also 11.2±2.26 
in men and 8.50±2.12 in women, significantly higher 
in men than in women (P=0.002).  Also, the disease 
severity requiring hospitalization in the ICU was 
higher in men than women (P=0.001). Thirty-five 
people with abnormal LFT spent more than 15 days 
in ICU compared with 27 in the opposite group. The 
overall death rate in COVID-19 patients was 38 
patients (27 men and 11 women), indicating a 
significant difference between the two genders 
(P=0.001). There were 21 deaths (30.8%) in patients 
with liver dysfunction and 17(32.6%) death in patients 
in the other group with regular liver function tests 
(Table 2). 
In autopsies on four non-survived subjects, liver and 
gastrointestinal involvements were found in all of 
them. Also, liver biopsy on three dead subjects 
revealed positive PCR tests in all three cases. 
Of 38 non-survived subjects, the D-dimer was checked 
in 8, which led to a positive result in 7 (87.5%). The 
blood group of O in 26 (68.4%), history of diabetes 
mellitus in 17 (25.0%) and elevated direct bilirubin in 
10 (14.7%). In general, nine patients were readmitted 
to ICU after discharging from the hospital, that one of 
them died. 
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Discussion 
There are various hypotheses about liver dysfunction 
in patients with COVID-19. Like the first hypothesis, 
the liver impairment may result from direct invasion 
of the COVID-19 virus to the liver tissue. The virus 
is known to be one of the wild pathogens for viral 
hepatitis.  Approximately 2–10% of patients with 
COVID-19 present with diarrhea and SARS-CoV-2 
RNAs have been detected in stool and blood 
samples. This evidence implicates the possibility of 
viral exposure in the liver26. Second, the presence of 
angiotensin-converting enzyme 2 (ACE2) receptors 
in different organs such as the liver suggest that 
SARS-CoV-2 can enter the target cell by binding to 
the ACE2 receptor virus replicates and subsequently 
infects other cells in the lung, heart and liver 
tissues27,28. Moreover, it seems that the inflammatory 
reactions following exposure to virus antigen can 
also be another potential mechanism for injuring vital 
organs such as the liver. In this regard, increased 
inflammatory cytokines such as interleukin 6 and 10 
are solid defendants for disease severity and vital 
organ involvement29.  
The literature (Table 3) indicates various liver 
parameters and poor outcomes following liver 
involvement in patients with COVID-19. In this 
regard, the serum levels of liver enzymes, serum 
bilirubin and LDH widely varied in the affected 
patients. Moreover, the mortality rate in patients 
suffering liver injury varied widely, with a range of 
0.0% to 62.0% in the follow-up from 24 to 51 days 
after admission30-36. The adverse effects of COVID-
19 on liver function are very dependent on different 
underlying factors such as disease severity and 
progression, co-morbidities, and the presence of 
different confounders affecting liver function (that 
should be excluded in study planning) and also the 
difference in the follow-up time. However, it is 
necessary to mention a few points. First, severe 
pulmonary and renal involvement can be concurrent. 
Second, liver injuries leading to metabolic 
disturbances can deteriorate the patients’ condition 
and even lead to death. As shown in a meta-analysis 
by Parohan et al. in 202037, higher serum levels of 
AST, ALT, and Total Bilirubin and lower serum 
levels of Albumin were associated with a significant 
increase in the severity of COVID-19 disease. In our 
study, elevated direct Bilirubin was also significantly 
associated with higher death rates and higher ICU 
hospitalization. Overall, a serum bilirubin level of 
more than 3mg/dl was associated with a higher 
likelihood of death in patients with liver dysfunction.  
Third, impairing liver functional parameters is a 
common finding in COVID-19 patients, significantly 
increasing Bilirubin, AST and ALT levels, and LDH. 
Guan et al. 26 showed elevated levels of AST in 18·2% 
of patients with the non-severe disease and 39·4% of 
patients with severe disease, while elevated levels of 
ALT in 19·8% and 28·1% of patients in Huang, et al. 
study32 was seen, respectively. Patients with severe 
COVID-19 had an increased incidence of abnormal 
liver function so that elevated AST levels were found 
in 62% and 25% of patients with and without ICU 
admission, respectively. In our study, the most 
common changes in liver-related parameters were 
elevated INR followed by elevated ALP. In general, 
despite the limited evidence, some baseline parameters 
appear to be associated with an increased likelihood of 
liver involvement, such as male gender, blood group 
of O, increased serum bilirubin level, history of 
uncontrolled diabetes mellitus, and elevated LDH, 
which should be evaluated in further studies. 
Collecting this information helps to justify the 
common cause of liver involvement and its poor 
consequences in patients with COVID-19. 
Conclusion 
We found that SARS-CoV-2 may infect the bile duct 
cells and cause abnormal liver function in patients 
with COVID-19 disease.  Liver injuries are common 
findings in patients suffering COVID-19 infection and 
leading to poorer outcomes. Serum bilirubin level 
more than 3mg/dl was associated with higher mortality 
in patients with liver damage. 
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